Search Results

Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.

Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.

In anticipation of Cord Blood Awareness Month this July, Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, announced the formation of the Be The Match BioTherapies Cord Blood Bank Alliance.

Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Cryoport, a leading global provider of innovative products and services to the fast-growing cell & gene therapy industry enabling the future of medicine for a new era of life sciences, announced a new strategic partnership.

The National Marrow Donor Program® /Be The Match® and Be The Match BioTherapies® launched a new web resource page and free white paper, “Paving the way to successful cell therapy clinical trials with a comprehensive approach and patient support,” to mark Clinical Trials Day 2023.

Be The Match BioTherapies® announced it is offering CIBMTR® Clinical Research Organization Services, which allows sponsors to significantly reduce the time required to launch and execute high-impact clinical trials.

With fewer biopharmas making or planning workforce reductions so far year over year, layoff round size and M&A impact on headcounts will likely shape the number of employees who are ultimately on the chopping block.

NMDP BioTherapies ℠, formerly Be The Match BioTherapies unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.